Logo image of SEPN

SEPTERNA INC (SEPN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SEPN - US81734D1046 - Common Stock

27.98 USD
+0.1 (+0.36%)
Last: 1/2/2026, 8:00:02 PM
27.98 USD
0 (0%)
After Hours: 1/2/2026, 8:00:02 PM
Fundamental Rating

4

Taking everything into account, SEPN scores 4 out of 10 in our fundamental rating. SEPN was compared to 191 industry peers in the Pharmaceuticals industry. While SEPN has a great health rating, there are worries on its profitability. SEPN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SEPN has reported negative net income.
In the past year SEPN had a positive cash flow from operations.
SEPN Yearly Net Income VS EBIT VS OCF VS FCFSEPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of SEPN (-12.88%) is better than 63.87% of its industry peers.
SEPN has a better Return On Equity (-14.00%) than 70.16% of its industry peers.
Industry RankSector Rank
ROA -12.88%
ROE -14%
ROIC N/A
ROA(3y)-30.64%
ROA(5y)N/A
ROE(3y)-35.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEPN Yearly ROA, ROE, ROICSEPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

SEPN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEPN Yearly Profit, Operating, Gross MarginsSEPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 0 -10K -20K -30K

More info and screens

8

2. Health

2.1 Basic Checks

SEPN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SEPN has more shares outstanding
There is no outstanding debt for SEPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SEPN Yearly Shares OutstandingSEPN Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 10M 20M 30M 40M
SEPN Yearly Total Debt VS Total AssetsSEPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 20.53 indicates that SEPN is not in any danger for bankruptcy at the moment.
SEPN has a Altman-Z score of 20.53. This is amongst the best in the industry. SEPN outperforms 88.48% of its industry peers.
SEPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 20.53
ROIC/WACCN/A
WACC9.37%
SEPN Yearly LT Debt VS Equity VS FCFSEPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

SEPN has a Current Ratio of 27.77. This indicates that SEPN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 27.77, SEPN belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
SEPN has a Quick Ratio of 27.77. This indicates that SEPN is financially healthy and has no problem in meeting its short term obligations.
SEPN has a Quick ratio of 27.77. This is amongst the best in the industry. SEPN outperforms 94.76% of its industry peers.
Industry RankSector Rank
Current Ratio 27.77
Quick Ratio 27.77
SEPN Yearly Current Assets VS Current LiabilitesSEPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SEPN have decreased strongly by -53868.89% in the last year.
SEPN shows a strong growth in Revenue. In the last year, the Revenue has grown by 611.92%.
EPS 1Y (TTM)-53868.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.13%
Revenue 1Y (TTM)611.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12113.07%

3.2 Future

The Earnings Per Share is expected to grow by 11.05% on average over the next years. This is quite good.
The Revenue is expected to grow by 112.19% on average over the next years. This is a very strong growth
EPS Next Y85.32%
EPS Next 2Y36.97%
EPS Next 3Y21.11%
EPS Next 5Y11.05%
Revenue Next Year5347.19%
Revenue Next 2Y997.41%
Revenue Next 3Y324.44%
Revenue Next 5Y112.19%

3.3 Evolution

SEPN Yearly Revenue VS EstimatesSEPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SEPN Yearly EPS VS EstimatesSEPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 -2 -4 -6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

SEPN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SEPN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SEPN Price Earnings VS Forward Price EarningsSEPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, SEPN is valued cheaply inside the industry as 88.48% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 12.14
EV/EBITDA N/A
SEPN Per share dataSEPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

SEPN's earnings are expected to grow with 21.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.97%
EPS Next 3Y21.11%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SEPN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SEPTERNA INC

NASDAQ:SEPN (1/2/2026, 8:00:02 PM)

After market: 27.98 0 (0%)

27.98

+0.1 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-25 2026-03-25
Inst Owners99.59%
Inst Owner Change0.23%
Ins Owners3.15%
Ins Owner Change0.35%
Market Cap1.25B
Revenue(TTM)22.05M
Net Income(TTM)-58.81M
Analysts81.82
Price Target30.8 (10.08%)
Short Float %2.98%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-137.48%
Min EPS beat(2)-163.84%
Max EPS beat(2)-111.11%
EPS beat(4)1
Avg EPS beat(4)-68.2%
Min EPS beat(4)-163.84%
Max EPS beat(4)9.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-69.38%
Min Revenue beat(2)-98.97%
Max Revenue beat(2)-39.79%
Revenue beat(4)2
Avg Revenue beat(4)3.63%
Min Revenue beat(4)-98.97%
Max Revenue beat(4)114.71%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.16%
PT rev (3m)31.3%
EPS NQ rev (1m)-0.45%
EPS NQ rev (3m)-49.5%
EPS NY rev (1m)2.71%
EPS NY rev (3m)-3352.37%
Revenue NQ rev (1m)6.86%
Revenue NQ rev (3m)-44.39%
Revenue NY rev (1m)3.83%
Revenue NY rev (3m)-49.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 56.82
P/FCF 12.14
P/OCF 12.02
P/B 2.98
P/tB 2.98
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)2.3
FCFY8.23%
OCF(TTM)2.33
OCFY8.32%
SpS0.49
BVpS9.38
TBVpS9.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.88%
ROE -14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 467.93%
ROA(3y)-30.64%
ROA(5y)N/A
ROE(3y)-35.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 66.94%
Cap/Sales 4.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.77
Quick Ratio 27.77
Altman-Z 20.53
F-Score5
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)237.63%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53868.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%102.13%
EPS Next Y85.32%
EPS Next 2Y36.97%
EPS Next 3Y21.11%
EPS Next 5Y11.05%
Revenue 1Y (TTM)611.92%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%12113.07%
Revenue Next Year5347.19%
Revenue Next 2Y997.41%
Revenue Next 3Y324.44%
Revenue Next 5Y112.19%
EBIT growth 1Y-77.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.08%
EBIT Next 3Y-7.32%
EBIT Next 5YN/A
FCF growth 1Y-67.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.24%
OCF growth 3YN/A
OCF growth 5YN/A

SEPTERNA INC / SEPN FAQ

What is the fundamental rating for SEPN stock?

ChartMill assigns a fundamental rating of 4 / 10 to SEPN.


Can you provide the valuation status for SEPTERNA INC?

ChartMill assigns a valuation rating of 2 / 10 to SEPTERNA INC (SEPN). This can be considered as Overvalued.


Can you provide the profitability details for SEPTERNA INC?

SEPTERNA INC (SEPN) has a profitability rating of 1 / 10.